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Objectives. This project tested two fundamental hypotheses: 
1) Protamine sulfate has a direct and negative effect on myocyte 
contractile processes; 2) the negative effects of protamine on 
myocyte contractility will be enhanced in the setting of chronic left 
ventricular dysfunction. 
Background. An increasing number of patients undergoing 
cardiac and vascular surgical procedures have underlying chronic 
left ventricular dysfunction. Protamine sulfate is commonly re- 
quired during these surgical procedures but has been associated 
with left ventricular dysfunction. However, it is not known whether 
protamine may have a direct and selective effect on myocyte 
contractility in the setting of chronic left ventricular dysfunction. 
Methods. This study examined the direct effects of protamine 
on isolated myocyte contractile function in 10 control pigs and 10 
pigs with dilated cardiomyopathy induced by supraventricular 
tachycardia (rapid atrial pacing at 240 beats/min for 3 weeks). 
Myocyte contractile function was measured by videomicroscopy at
baseline and with 10, 20, 40 or 80 #g/ml of protamine. In a second 
series of experiments, myocytes were preincubated with protamine 
and then stimulated with the beta-adrenergic agonist isoprotere- 
nol (25 nmol/liter). 
Results. In the presence of 20 #g/ml of protamine, myocyte 
contractile function was unaffected in the control group but 
decreased by 40% from baseline values in the supraventricular 
tachycardia group. With 10 #g/ml of protamine, myocyte beta- 
adrenergic responsiveness was reduced by 25% in the supraven- 
tricular tachycardia group with no change in the control group. In 
the presence of 40 and 80 #g/ml of protamine, myocyte contractile 
function decreased in both groups. However, 40/~g/ml of prota- 
mine caused a more pronounced ecline in myocyte function and 
beta-adrenergic responsiveness in the supraventricular tachycar- 
dia group. 
Conclusions. An increased sensitivity to the depressive ffects of 
protamine on myocyte contractile function and beta-adrenergic 
responsiveness occurred in this model of chronic left ventricular 
dysfunction. These results suggest hat patients with underlying 
cardiac disease may have an increased susceptibility to a sudden 
compromise of left ventricular contractile performance after 
protamine administration. 
(J Am Coil Cardiol 1995;25:773-80) 
The anticoagulant effects of heparin are routinely reversed by 
the administration of the polycationic peptide protamine sul- 
fate. However, alterations in the hemodynamic state and 
life-threatening anaphylactic reactions have been associated 
with the administration of protamine in patients (1-4). Addi- 
tionally, past clinical and experimental studies (5-11) have 
suggested that the administration of protamine may have a 
depressive effect on left ventricular function. However, most of 
these past studies were performed in hearts without disease. 
Recently, our laboratory demonstrated that protamine directly 
depressed the contractile function of myocytes i olated from 
normal porcine left ventricle. However, in the clinical setting 
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protamine is usually administered to patients with underlying 
cardiac disease. Thus, one objective of the present study was to 
examine the direct effects of protamine on myocyte contractile 
function in the setting of cardiomyopathic disease. 
In chronic left ventricular dysfunction there are changes in 
the myocardial beta-adrenergic receptor system that result in 
diminished responsiveness to beta-adrenergic agonists (12,13). 
These changes are of importance because beta-adrenergic 
agonists are frequently used to improve left ventricular pump 
performance in patients after cardiovascular surgery (14). 
Thus, protamine and beta-adrenergic agonists may be used 
concomitantly in patients with chronic left ventricular dysfunc- 
tion undergoing cardiovascular surgery. However, it is not 
known whether the administration ofprotamine directly affects 
myocyte beta-adrenergic responsiveness in the setting of 
chronic left ventricular dysfunction. Therefore, a second ob- 
jective of this study was to determine the effect of protamine 
on myocyte beta-adrenergic responsiveness in the setting of 
cardiomyopathic disease. Cardiomyopathic heart disease is a 
significant cause of chronic congestive heart failure (15,16). 
Past studies have demonstrated that chronic tachycardia in 
humans and animals causes a dilated cardiomyopatby (17-20). 
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Specifically, this laboratory has demonstrated that chronic 
supraventricular tachycardia causes left ventricular dilation 
and dysfunction as well as abnormalities in myocyte contractile 
function (19). Accordingly, the current project used this model 
of supraventricular tachycardia-induced cardiomyopathy to
test the central hypothesis that with the development of 
chronic left ventricular failure, myocyte function will be more 
vulnerable to the negative contractile and inotropic effects of 
protamine. 
Methods  
Experimental design. Fourteen age- and weight-matched 
pigs (Yorkshire strain, all aged 6 months and weighing 28 kg) 
were randomly assigned to one of two groups: 1) chronic 
supraventricular t chycardia group, 10 pigs subjected to su- 
praventricular pacing tachycardia (240 beats/rain) for 3 weeks, 
and 2) sham control group, 10 pigs treated in identical fashion 
with the exception of the pacing protocol. The pacing protocol 
was performed as previously described (19). Briefly, stimulat- 
ing electrodes (Spectrax, Medtronic, Inc.) modified to pace at 
400 beats/rain were sutured onto the left atrium. After the 
animals recovered from the surgical procedure, atrial pacing at 
240 beats/rain was initiated. Electrocardiograms (ECGs) were 
obtained frequently during the pacing protocol to ensure the 
presence of 1:1 atrioventricular conduction. All animals were 
treated and cared for in accordance with the National Insti- 
tutes of Health Guide for the Care and Use of Laboratory 
Animals (National Research Council, 1985; NIH publ. no. 
86-23). 
Left ventricular function studies. On the day of study, 
the pigs were sedated with 10 mg of midazolam (Versed, 
Hoffman-La Roche), placed in a custom-designed sling that 
allowed the animal to rest comfortably, an ECG established, 
and the pacemaker deactivated (supraventricular tachycardia 
group only). Two-dimensional nd M-mode echocardiographic 
studies (ATL Ultramark VI, 2.25 MHz transducer) were used 
to image the left ventricle from a right parasternal pproach. 
Echocardiographic measurements were performed as previ- 
ously described (19). Left ventricular fractional shortening, 
computed as End-diastolic dimension - End-systolic dimen- 
sion/End-diastolic dimension, was expressed as a percent. 
After left ventricular function measurements the pig was 
anesthetized with isoflurane (2.0%/1.5 liters/rain) and nitrous 
oxide (0.5 liters/rain), a sternotomy was performed and the 
heart quickly extirpated and placed in an oxygenated Krebs 
solution. The region of the left ventricular f ee wall comprising 
the left circumflex coronary artery was dissected free, and the 
artery was cannulated, and prepared for myocyte isolation. 
Myocyte isolation and contractile function measurements. 
With the use of methods previously described by this labora- 
tory (21), an oxygenated modified Krebs solution containing 
aerobic substrates and collagenase (0.5 mg/ml, Worthington, 
type I1; 146 U/rag) was perfused and recirculated through the 
cannulated circumflex artery for 20 rain. The tissue was then 
minced into 2-ram sections and added to an oxygenated 
solution containing 400/xmol/liter calcium chloride and colla- 
genase (0.5 mg/ml). The tissue and solution were gently 
agitated and at 5-min intervals, the supernatant was removed, 
filtered and the cells allowed to settle. The myocyte pellet was 
then resuspended in standard culture medium (M199, 2 retool/ 
liter calcium, Gibco Laboratories). Isolated myocytes were 
placed in a thermostatically controlled chamber (37°C) fitted 
with a coverslip on the bottom for imaging on an inverted 
microscope (Axiovert 1M35, Zeiss Inc., Oberkochen, Germa- 
ny). Myocyte contractions were elicited by field stimulating the 
tissue chamber at 1 Hz (Sll, Grass Instruments) using current 
pulses of 5-ms duration and voltages 10% above contraction 
threshold. The polarity of the platinum stimulating electrodes 
was alternated to prevent the build up of electrochemical 
by-products. Myocyte contractions were imaged using a 
charge-coupled device with a noninterlaced scan rate of 240 Hz 
(GPCD60, Panasonic). Myocyte contraction profiles were an- 
alyzed by techniques previously well described by this labora- 
tory (19,21,22). Stimulated myocytes were allowed a 5-rain 
stabilization period before the following variables were com- 
puted: percent shortening (%), peak velocity of shortening 
(~m/s), peak velocity of lengthening (/xm/s), time to peak 
contraction (ms) and total contraction duration (ms). These 
variables were calculated for each contraction and the results 
averaged for 20 contractions. After collection of baseline 
indexes of myocyte function, the protocols described in the 
following paragraphs were instituted. 
Experimental protocol. Myocytes from control pigs and 
pigs with cardiomyopathy induced by supraventricular tachy- 
cardia were randomly assigned to the following treatment 
protocols. 
Protamine. In both groups of myocytes, measurements of 
contractile function were performed at baseline and repeated 
after exposure to either 10, 20, 40 or 80 p~g/ml of crystalline 
protamine sulfate suspended in 0.1 N saline solution (Elkins- 
Sinn, Inc.). These concentrations of protamine approximate 
the serum concentrations obtained in patients when protamine 
is given in doses of 0.63, 1.25, 2.5 and 5 mg/kg body weight, 
respectively (5,7). 
Beta-adrenergic re eptor stimulation. After baseline contrac- 
tile measurements, both groups of myocytes were exposed to 
the beta-adrenergic agonist isoproterenol (25 nmol/liter; Sig- 
ma), and measurements were repeated. This concentration of
isoproterenol has been shown (19,21) to elicit the 100% 
maximal response in contractile function of porcine myocytes. 
In a separate series of experiments, myocytes preincubated 
with either 10, 20, 40 or 80/xg/ml of protamine were exposed 
to 25 nmol/liter of isoproterenol and measurements of con- 
tractile function obtained. 
Heparin and the heparin-protamine complex. In this final 
series of experiments, myocyte contractile function in both 
groups of myocytes was measured 1) at baseline, 2) after the 
addition of 8 IU/ml of heparin (Beef lung, Upjohn), and 
3) after the sequential addition of 8 IU/ml of heparin and 
80 ~g/ml of protamine. The heparin concentration selected 
was calculated by using the relation 1 mg of heparin is bound 
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Table 1. Left Ventricular Function After Chronic 
Supraventricular Tachycardia 
Control Group SVT Group 
(n = 10) (n -  10) 
Left ventricular weight/body weight (&/kg) 2.8 ± 0.2 3.1 ± 0.3 
Intrinsic heart rate (beats/rain) 109 + 6 160 _+ 5* 
End-diastolic dimension (cm) 3.6 _+ 0.2 5.1 ± 0.2* 
Fractional shortening (%) 34 ± 3 12 _+ 2* 
*p < 0.05 versus values in control pigs. Values presented are mean value -+ 
SEM. SVT group = group with cardiomyopathy induced by chronic supraven- 
tricular tachycardia (3 weeks of rapid atrial pacing at 240 beats/rain). 
by 1 mg of protamine (23). The effect of these compounds on 
myocyte beta-adrenergic responsiveness was examined by add- 
ing 25 nmol/liter of isoproterenol to the respective treatment 
groups as described earlier. 
The pH of the media in the experimental chamber was 
routinely checked to ascertain whether any changes occurred 
after the addition of protamine. Chambers with standard 
culture media (pH = 7.49) and media with pro?amine (pH = 
7.53) were not significantly different. 
Data analysis. Multivariate analysis of variance was used 
to compare myocyte function between groups and drug treat- 
ments. If analysis of variance revealed significant differences, 
mean separation was performed by using Bonferroni probabil- 
ities (24). Results are presented as mean value _+ SEM. A p 
value < 0.05 was considered statistically significant. 
Resu l ts  
All of the pigs undergoing chronic supraventricular tachy- 
cardia developed symptoms of congestive heart failure after 3 
weeks of pacing. These included dyspnea, rales, peripheral 
edema and ascites. 
Left ventricular function. Indexes of left ventricular pump 
function in control pigs and pigs with supraventricular tachy- 
cardia are summarized in Table 1. End-diastolic dimension 
increased and fractional shortening decreased in the group 
with supraventricular tachycardia compared with the control 
group. The development of supraventricular tachycardia- 
induced cardiomyopathy was not accompanied by changes in 
left ventricular mass. Thus, consistent with past reports (19,20), 
3 weeks of chronic supraventricular tachycardia caused a 
dilated cardiomyopathy. 
Myocyte contractile function. Baseline. Myocytes were 
successfully isolated from all pigs used in the present study. A 
total of 168 control myocytes and 158 myocytes from the 
supraventricular tachycardia group (minimum 15 myocytes/ 
pig) were studied at baseline before being randomly assigned 
to a treatment group. Steady state contractile function at 
baseline for myocytes in the control and supraventricular 
tachycardia groups is summarized in Table 2. Myocyte length 
at rest increased significantly in the supraventricular tachycar- 
dia group compared with that in the control group (187 _+ 3 vs. 
132 _+ 2/~m, p < 0.05). Myocyte length at rest was similar for 
all treatment protocols. Myocyte percent and velocity of 
shortening were significantly lower in the supraventricular 
tachycardia group than in the control group. Thus, consistent 
with past reports (19,20), the development of supraventricular 
tachycardia-induced cardiomyopathy resulted in increased 
myocyte length at rest and reduced indexes of myocyte con- 
tractile performance. 
Protamine. Myocyte contractile function in the presence of 
increasing concentrations of protamine for myocytes in the 
control and supraventricular tachycardia groups is summarized 
in Table 2. The effects of protamine with respect o changes in 
myocyte velocity of shortening from baseline values for the two 
groups are illustrated in Figure 1. In the control group, 
Table 2. Myocyte Contractile Performance in Control Pigs and Pigs With Supraventricular Tachycardia-Induced Cardiomyopathy: 
Effects of Protamine 
Protamine 
Baseline 10/~g/ml 20 ~g/ml 40 ~g/ml 80/~g/ml 
Percent shortening (%) 
Control group 
SVT group 
Velocity. of shortening (~m/s) 
Control group 
SVT group 
Velocity of lengthening (t~m/s) 
Control group 
SVT group 
Time to peak contraction (ms) 
Control group 
SVT group 
Total contraction duration (ms) 
Control group 
SVT group 
4.9 +- 0.1 5.0 +- 0.3 4.6 -+ 0.3 3.9 -+ 0.2t 3.1 +- 0.3? 
2.0 + 0.1" 1.8 ± 0.3* 1.1 + 0.1*t 1.2 ± 0.1*t 0.8 -+ 0.1"? 
51.6 -+ 1.3 50.3 -+ 3.3 49.0 -+ 3.3 39.6 -+ 2.7? 33.5 + 2.6t 
32.1 ± 1.1' 28.4 ± 2.9* 20.1 ± 1.6*t 19.5 -+ 1.8"? 15.7 - 1.6'? 
56.7 -+ 1.7 55.1 + 3.4 56.5 -+ 4.5 52.3 -+ 4.8 38.2 -+ 4.2t 
29.4 + 1.2" 27.6 ± 4.5* 18.0 ± 2.0"? 16.6 ± 1.6*t 13.2 -+ 1.4*t 
265.9 -+ 5.4 286.6 + 13.1 238.0 -+ 7.8t 263.7 -+ 9.6 254.4 -+ 10.4 
229.7 + 4.9* 217.9 + 7.5* 195.8 ± 10.5*t 212.2 -+ 8.1' 191.9 -+ 9.9*? 
510.1 + 8.2 491.6 + 12.7 432.4 + 14.1t 449.1 + 19.2t 505.1 -+ 20.9 
450.1 -+ 9.6* 387.6 + 18.5'? 390.6 -+ 23.9t 421.1 -+ 19.6 348.5 -+ 27.1"? 
*p < 0.05 versus control myocytes, tp < 0.05 versus baseline value. Values presented are mean value ± SEM. Abbreviations a in Table 1. 
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Figure 1. Percent change in myocyte velocity of shortening from 
baseline values after administration f 10, 20, 40 or 80 p,g/ml of 
protamine incontrol myocytes and in myocytes with cardiomyopathy 
induced by supraventricular tachycardia (SVT). In the control group, 
myocyte velocity of shortening was not changed from baseline values 
by the addition of either 10 or 20/~g/ml ofprotamine. However, inthe 
supraventricular t chycardia group, there was a significant decrease 
(p < 0.05) in percent change from baseline values with the addition of 
10 p,g/ml of protamine, and the addition of 20 p,g/ml caused a 
significant (p < 0.05) decline in myocyte velocity of shortening from 
both baseline and values obtained with 10/~g/ml. Inthe presence of40 
/zg/ml of pro?amine, percent change in myocyte velocity of shortening 
decreased from baseline values in both groups, but the decrease was 
significantly greater in the supraventricular tachycardia group (*p < 
0.05). Both groups howed a further dose-dependent decrease in
percent change from baseline in the presence of 80 /~g/ml of prota- 
mine, with no difference between the groups. 
myocyte contractile function was unchanged in the presence of 
10 or 20 ~g/ml of protamine. In the supraventricular t chycar- 
dia group, 10/~g/ml of protamine had a significant effect on 
myocyte velocity of shortening when examined as a percent 
change from baseline values (Fig. 1). In marked contrast o 
results in the control myocytes, 20 ~g/ml of protamine in the 
supraventricular t chycardia group caused a significant reduc- 
tion in contractile function from baseline values, with both 
percent and velocity of shortening decreasing by >35% from 
baseline (no protamine) values. In the presence of 40/~g/ml of 
protamine, myocyte contractile function decreased inboth the 
control and supraventricular t chycardia groups. Furthermore, 
40/~g/ml of protamine caused asignificantly greater reduction 
in the indexes of myocyte contractile function in the supraven- 
tricular tachycardia group than in the control group (Fig. 1). 
The presence of 80/~g/ml of protamine resulted in a continued 
downward trend in all indexes of contractile function in both 
myocyte groups with no differences between groups. In addi- 
tion, analysis of variance revealed that a significant interaction 
existed between the two groups and the presence of pro?amine. 
Specifically, the analysis of variance model revealed that 
pro?amine had a selective depressive ffect on myocyte con- 
tractile function in the supraventricular tachycardia group 
compared with that in the control group (F = 3.24, p = 0.02). 
Thus, the presence of protamine had a direct depressive effect 
on myocyte contractile function. More important, he contrac- 
tile function of myocytes in the supraventricular t chycardia 
group was depressed atlower concentrations of protamine (10 
and 20/~g/ml) and to a greater degree at higher concentrations 
of protamine (40 p,g/ml) than was that of the control myocytes. 
Beta-adrenergic receptor stimulation. In this series of exper- 
iments, the dose-dependent effects of pro?amine on myocyte 
beta-adrenergic responsiveness in both the control and su- 
praventricular tachycardia groups were examined (Table 3). 
Consistent with past reports (19-21), the addition of isopro- 
terenol alone significantly increased myocyte contractile per- 
formance in both groups. The direct effects of protamine on 
myocyte beta-adrenergic responsiveness with respect to 
Table 3. Myocyte Beta-Adrenergic Responsiveness in Control Pigs and Pigs With Supraventricular T chycardia-Induced Cardiomyopathy: 
Effects of Protamine 
lsoproterenol + Isoproterenol + Isoproterenol + Isoproterenol +
Isoproterenol 10 ~g/ml of 20 p,g/ml of 40 ,~g/ml of 80 tzg/ml of 
Baseline Alone Protamine Protamine Protamine Protamine 
Percent shortening (%) 
Control group 4.9 + 0.1 8.6 _+ 0.5? 8.8 z 0.5+ 7.6 _+ 0.5t 6.7 _+ 0.5t$ 5.0 _+ 0.85 
SVT group 2.0 _+ 0.1" 4.7 _+ 0.3"? 4.5 = 0.2*t 2.8 + 0.3"?$ 2.6 -+ 0.4*$ 2.3 -+ 0.4*$ 
Velocity of shortening (/~m/s) 
Control group 51.6 _+ 1.3 103.8 + 5.7t 110.3 + 3.0t 106.9 _+ 5.9t 76.5 + 5.2t$ 64.8 _+ 10.05 
SVT group 32.1 _+ 1.1' 81.4 _+ 4.1*t 67.8 -+ 3.2't$ 58.7 = 6.4't$ 54.5 _+ 6.5"t~ 46.9 _+ 5.1't$ 
Velocity of lengthening (~m/s) 
Control group 56.7 + 1.7 94.0 _+ LOt 113.7 _+ 4.8?$ 108.6 +_ 6.5? 79.0 + 4.6t 55.2 _+ 9.15 
SVT group 29.4 _+ 1.2" 62.2 _+ 5.0"? 56.0 + 2.1"? 51.1 +_ 5.9"t 46.9 _+ 5.9"+ 38.7 -+ 5.6*$ 
Time to peak contraction (ms) 
Control group 265.9 + 5.4 225.5 _- 10.0t 216.2 _+ 17.77 187.2 _+ 12.475 244.5 _+ 19.3 244.9 + 21.1 
SVT group 229.7 _+ 4.9* 195.2 - 9.5"t 166.2 _+ 8.5't$ 176.2 _+ 7.9? 192.2 _+ 19.9 165.3 _+ 11.1'?$ 
Total contraction duration (ms) 
Control group 510.1 _+ 8.2 490.6 = 30.2 355.8 + 33.0?:1 357.7 -+ 17.775 454.5 -+ 50.4 516.9 -+ 45.9 
SVT group 450.1 -+ 9.6* 455.4 _+ 25.3 326.8 +- 17.775 354.8 -+ 17.6?$ 388.3 -+ 25.9t$ 360.1 -+ 26.7"t$ 
*p < 0.05 versus control myocytes, tp < 0.05 versus baseline value. Sp < 0.05 versus isoproterenol (25 nmol/liter) alone. Values presented are mean value _+ SEM. 
Abbreviations as in Table 1. 
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Figure 2. Percent change in myocyte velocity of shortening from 
values achieved with administration of isoproterenol only in control 
myocytes and in myocytes with cardiomyopathy induced by supraven- 
tricular tachycardia (SVT) after preincubation with either 10, 20, 40 or 
80 ~g/ml of protamine followed by stimulation with 25 nmol/liter of 
isoproterenol. Preincubation with either 10 or 20 gg/ml of protamine 
did not alter myocyte contractile response to isoproterenol in the 
control group but caused a significant decrease in contractile response 
to isoproterenol in the supraventricular tachycardia group (*p < 0.05 
vs. control myocytes). In the presence of 40 t~g/ml of protamine, 
myocyte beta-adrenergic responsiveness decreased in both groups, 
with a further dose-dependent decline observed in the presence of 
80 ~g/ml of protamine. 
Table 4. Myocyte Contractile Performance in Control Pigs and Pigs 
With Supraventricular Tachycardia-Induced Cardiomyopathy: 
Effects of Heparin and the Heparin-Protamine Complex 
Heparin + 
Baseline Heparin Protamine 
Percent shortening (%) 
Control group 
SVT group 
Velocity of shortening (~m/s) 
Control group 
SVT group 
Velocity of lengthening (~m/s) 
Control group 
SVT group 
Time to peak contraction (ms) 
Control group 
SVT group 
Total contraction duration (ms) 
Control group 
SVT group 
4.9 _+ 0.1 4.5 • 0.2 4.7 _+ 0.3 
1.9 z 0.1" 1.6 + 0.2* 2.0 _+ 0.3* 
51.9 _+ 1.4 48.7 + 3.1 50.5 _+ 4.6 
32.8 + 1.4' 30.6 + 4.5* 30.4 _+ 6.9* 
57.7 _+ 1.9 49.7 + 3.2 53.4 _+ 4.0 
30.2 _+ 1.4' 27.1 + 5.4* 27.6 _+ 7.9* 
266.9 + 5.7 246.6 + 14.6 235.0 _+ 22.0 
225.2 +_ 6.0* 237.5 + 19.2 282.6 _+ 26.9 
512.1 _+ 9.0 531.2 ~ 24.2 516.2 - 25.9 
441.3 _+ 12.6' 486.5 _+ 52.6 576.4 _+ 57.8 
*p < 0.05 versus control myocytes. Values presented are mean value + SEM. 
Heparin concentration = 8 IU/ml; protamine concentration = 80 /~g/ml. 
Abbreviation as in Table 1. 
was observed in either group in the presence of heparin alone 
or the heparin-protamine complex (data not shown). 
changes in myocyte velocity of shortening are illustrated in 
Figure 2. In control myocytes, preincubation with 10 or 20/~g/ml 
of protamine had no effect on myocyte beta-adrenergic respon- 
siveness. In marked contrast, beta-adrenergic responsiveness 
was significantly reduced in myocytes in the supraventricular 
tachycardia group that had been preincubated with 10 t~g/ml of 
protamine. For example, in this subgroup, 10 ~g/ml of prota- 
mine caused a 17% decrease in myocyte velocity of shortening 
from values obtained with isoproterenol a one. In the presence 
of both 20 Izg/ml of protamine and isoproterenol, percent 
shortening in the supraventricular tachycardia group de- 
creased by 35% and velocity of shortening decreased by 25% 
compared with values obtained with isoproterenol alone. In 
the presence of 40 ~g/ml of protamine, beta-adrenergic re- 
sponsiveness was reduced in myocytes in both the control and 
supraventricular tachycardia groups. Additionally, the pres- 
ence of 80/~g/ml of protamine caused a further reduction in 
myocyte beta-adrenergic responsiveness in both groups. Thus, 
whereas protamine caused a reduction in myocyte beta- 
adrenergic responsiveness in both groups, these effects were 
observed at a lower concentration i  the group with supraven- 
tricular tachycardia-induced cardiomyopathy. 
Heparin and the heparin-protamine complex. The effects of 
heparin and the heparin-protamine complex on contractile 
function in the control and supraventricular tachycardia myo- 
cyte groups are summarized in Table 4. In both groups the 
presence of either heparin alone or the heparin-protamine 
complex had no effect on baseline myocyte contractile func- 
tion. Similarly, no change in beta-adrenergic responsiveness 
Discussion 
Heparin is commonly used for anticoagulation i  patients 
undergoing cardiac and vascular surgical procedures. The 
effects of heparin are routinely reversed by the administration 
of the polycationic peptide protamine sulfate. Observations 
from a recent clinical study (9) suggested that patients with 
depressed left ventricular pump function are at increased risk 
for acute left ventricular dysfunction after administration of 
protamine. However, whether protamine has a direct and 
selective ffect on myocyte contractile performance with the 
development of chronic left ventricular dysfunction remained 
unknown. Accordingly, we addressed this issue by examining 
the direct effects of protamine on control and cardiomyopathic 
myocyte contractile function and beta-adrenergic responsive- 
ness. There were four significant findings in the present study. 
1) With the development of supraventricular tachycardia- 
induced cardiomyopathy, myocyte contractile function was 
reduced in the presence of low concentrations (10 or 20 ~g/ml) 
of protamine, whereas these concentrations had no effect on 
control myocytes. 2) In the presence of 40 ~g/ml of protamine, 
myocyte contractile function decreased inboth groups, but the 
reduction was significantly greater in the supraventricular 
tachycardia group. 3) 10 tzg/ml of protamine caused a signifi- 
cant reduction in myocyte beta-adrenergic responsiveness with 
the development of supraventricular tachycardia-induced car- 
diomyopathy but had no effect on control myocytes. 4) A 
higher concentration ofprotamine (80 ~g/ml) depressed myo- 
cyte contractile function and beta-adrenergic responsiveness 
equally in both groups of myocytes. 
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It has been well documented (1-3) that protamine admin- 
istration in patients can be accompanied by alterations in both 
systemic and pulmonary hemodynamics, and activation of the 
complement cascade and certain cytokines. The present study 
demonstrated that protamine had direct effects on myocyte 
contractile function and beta-adrenergic responsiveness inde- 
pendent of changes in loading conditions and extracellular 
influences. More important, it demonstrated that with the 
development of cardiomyopathic disease, myocytes were more 
vulnerable to the negative ffects of protamine on contractile 
function. Thus, this study for the first time presents direct 
evidence at the cellular level to suggest hat patients with 
underlying chronic left ventricular dysfunction may be more 
susceptible to the negative contractile and inotropic effects of 
protamine. 
Protamine and existing left ventricular dysfunction. Past 
clinical studies (9-11) have suggested that protamine may have 
an enhanced negative ffect on left ventricular pump function 
in patients with underlying left ventricular dysfunction. For 
example, Del Re et al. (9) reported that protamine infusion 
decreased left ventricular f actional shortening in patients with 
a preoperative ejection fraction of <50% but had no effect on 
patients with a normal ejection fraction. Additionally, Sethna 
et al. (10) observed that patients with poor left ventricular 
function during weaning from cardiopulmonary b pass had a 
significant decrease in cardiac index after protamine adminis- 
tration. Thus, these past reports as well as others (11) suggest 
that patients with depressed left ventricular pump function in 
the early postcardiopulmonary bypass period are more suscep- 
tible to the negative ffects of protamine. In the clinical setting, 
the changes in loading conditions and neurohormonal ctiva- 
tion that occur after cardiopulmonary b pass (25) make direct 
assessment of the effects of protamine on left ventricular 
contractile function problematic. The present study demon- 
strated a direct and enhanced epressive ffect of protamine 
on contractile function in the myocytes of pigs with supraven- 
tricular tachycardia-induced cardiomyopathy, independent of 
loading conditions or neurohormonal factors. Specifically, 20 
/xg/ml of protamine, which is equivalent to the serum concen- 
tration obtained in patients receiving a dose of 1.25 mg/kg 
(5,7), reduced contractile function and beta-adrenergic respon- 
siveness in myocytes in the supraventricular t chycardia group 
but had no effect on control myocytes. Additionally, 40/xg/ml 
of protamine (i.e., a clinical dose of 2.5 mg/kg) caused a 
decrease in contractile function in both myocyte groups, but 
the reduction was significantly greater in the supraventricular 
tachycardia group. The present study demonstrated that in the 
presence of a protamine concentration commonly encountered 
clinically, myocyte contractile function was unaffected in the 
control group but was significantly reduced in this model of 
cardiomyopathy. Thus, the present study provides evidence to 
suggest hat protamine may have a direct and selective nega- 
tive effect on myocyte contractile function in patients with 
preexisting left ventricular dysfunction. 
Beta-adrenergie agonists and protamine. Beta-adrenergic 
agonists can be used to augment left ventricular pump function 
during weaning from cardiopulmonary b pass (14). For exam- 
ple, Steen et al. (14) observed that patients with preoperative 
left ventricular dysfunction had a significant improvement in
cardiac index after the administration of beta-adrenergic ago- 
nists in the postcardiopulmonary bypass period. Given the 
importance of beta-adrenergic receptor stimulation in cardiac 
surgical procedures as well as the potential temporal relation 
with protamine administration, the present study examined the 
effects of protamine on myocyte beta-adrenergic responsive- 
ness in control and cardiomyopathic myocytes. A protamine 
concentration of 10 /xg/ml caused a reduction in myocyte 
beta-adrenergic responsiveness in the group with supraventric- 
ular tachycardia-induced cardiomyopathy but not in the con- 
trol group. Thus, with the development of cardiomyopathy, 
myocyte beta-adrenergic responsiveness was selectively in- 
fluenced by protamine. It has been well established 
(12,13,20,26,27) that alterations in the beta-adrenergic system 
occur with cardiomyopathic disease. Specifically, Bristow et al. 
(13) reported a reduction in the sarcolemmal beta-adrenergic 
receptor density as well as a partial uncoupling of the beta- 
adrenergic receptor in explanted cardiomyopathic hearts. 
Thus, their report and that of others (12,20,26,27) clearly 
demonstrate that fundamental alterations in the beta- 
adrenergic system occur in the setting of chronic left ventric- 
ular dysfunction. The present study demonstrated selective 
effects of protamine on myocyte beta-adrenergic responsive- 
ness in the setting of cardiomyopathic disease. Taken together, 
these results suggest hat an alternative method of inotropic 
support other than beta-adrenergic agonists may be necessary 
in patients with underlying left ventricular dysfunction requir- 
ing protamine administration. 
Protamine and heparin interaction. Protamine reverses 
the anticoagulant effects of heparin by binding to heparin in a 
1:1 fashion and forming a heparin-protamine complex (23). In 
the present study, heparin did not effect myocyte contractile 
function. Furthermore, subsequent addition of the positively 
charged protamine molecule presumably complexed with the 
heparin present in the myocyte media, thereby protecting the 
myocyte from the detrimental effects of the protamine mole- 
cule on contractile function and beta-adrenergic responsive- 
ness. These findings are consistent with previous work (6,28) 
suggesting that the addition of heparin ameliorates the de- 
pressed left ventricular function observed in the presence of 
protamine. Specifically, Wakefield et al. (6) reported that the 
depressed peak first derivative of left ventricular pressure 
(dP/dt) observed in the presence of protamine was reversed 
after the administration of heparin. Taken together, results 
from these past studies and the present study suggest hat the 
changes in left ventricular function observed clinically after 
protamine administration (1,2,4,9,11) may be due to the direct 
and negative ffects of the fraction of unbound protamine on 
myocyte contractile function. Furthermore, our present results 
suggest that cardiomyopathic myocytes are more sensitive than 
normal myocytes to the negative ffects of unbound protamine 
on contractile function and beta-adrenergic responsiveness. 
Our study employed a model of dilated eardiomyopathy 
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induced by chronic rapid atrial pacing in pigs. The induced 
chronic supraventricular tachycardia caused left ventricular 
and myocyte dysfunction consistent with past reports (19,20). 
Furthermore, tachycardia-induced dilated cardiomyopathy as 
been shown (20,26,27) to cause neurohormonal ctivation and 
depressed beta-adrenergic responsiveness. Thus, our model 
has many similarities to the clinical spectrum of cardiomyo- 
pathic disease. However, it may not address other cardiac 
disease, such as ischemic, valvular or hypertensive heart dis- 
ease, although it did provide a means for testing the hypothesis 
that protamine has a selective ffect on myocyte contractile 
processes in the setting of chronic left ventricular dysfunction. 
Our results demonstrated that protamine had an enhanced 
depressive ffect on the contractile function and inotropic 
responsiveness of cardiomyopathic myocytes compared with 
that in the control group. Isolated myocyte studies provide a 
means of examining myocyte contractile processes in the 
absence of neurohormonal influences. However, protamine is 
known to cause a variety of systemic effects, including release 
of cytokines and activation of the complement cascade (2-4). 
The experimental design of our study did not address these 
systemic effects of protamine. A final limitation of our study is 
that the effects of protamine on myocyte contractile function 
were examined promptly after drug administration and at only 
one time point. In the future, studies that examine myocyte 
function and structure after longer periods of exposure to 
protamine may be warranted. 
Protamine is composed largely of the amino acid arginine, 
which results in a high net positive charge (4). These highly 
charged amino acids found in protamine may interfere with the 
function of ion pumps, channels or exchangers. Evidence that 
protamine alters sarcolemmal function was provided by a 
report from Hu et al. (29) demonstrating that protamine 
caused allosteric onformational changes in sarcolemmal mus- 
carinic receptors. In addition, Lin et al. (5) reported changes in 
Purkinje action potentials with protamine, which suggests 
alterations in ionic homeostasis (30). Thus, although specific 
mechanisms by which protamine influences myocyte function 
remain speculative, probable contributory mechanisms in- 
clude alterations in sarcolemmal function and ionic homeosta- 
sis. Several past reports (20,26,27) have demonstrated that 
the development of tachycardia-induced cardiomyopathy is 
accompanied by significant changes in sarcolemmal func- 
tion. Specifically, abnormalities in the beta-adrenergic and 
sodium-potassium-adenosine triphosphatase ystems have been 
documented with the development of tachycardia-induced 
cardiomyopathy (27). Further, Perreault et al. (31) reported 
abnormalities in calcium homeostasis n dogs with pacing- 
induced heart failure. Thus, protamine may exacerbate intrin- 
sic abnormalities in sarcolemmal function and ionic homeosta- 
sis that exist with tachycardia-induced cardiomyopathy. 
Clinical implications. Our results demonstrate that with 
the development of tachycardia-induced dilated cardiomyopa- 
thy, myocyte contractile function was selectively depressed by a 
low concentration of protamine. These findings may have 
clinical significance because an increasing number of patients 
with underlying chronic left ventricular dysfunction are under- 
going cardiac surgical procedures (32). Furthermore, our study 
demonstrated that cardiomyopathic myocytes are more vulner- 
able to the negative inotropic effects of protamine after 
beta-adrenergic receptor stimulation. Because beta-adrenergic 
agonists are commonly used in conjunction with protamine, 
our data suggest that selection of an alternative inotropic agent 
not dependent on the beta-adrenergic system may be useful 
after protamine administration. It remains to be defined precisely 
how current protamine therapy may be modified by our finding 
that cardiomyopathic myocytes are more sensitive than normal 
myocytes to the negative contractile ffects of protamine. 
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